Azitra, Inc. (AZTR)
ASE – Real Time Price. Currency in USD
0.22
-0.01 (-4.72%)
At close: May 12, 2026, 4:00 PM EDT
0.22
+0.00 (1.77%)
After-hours: May 12, 2026, 7:50 PM EDT
Find any stock by ticker or company name

ASE – Real Time Price. Currency in USD
0.22
-0.01 (-4.72%)
At close: May 12, 2026, 4:00 PM EDT
0.22
+0.00 (1.77%)
After-hours: May 12, 2026, 7:50 PM EDT
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
| Name | Position |
|---|---|
| Dr. Travis M. Whitfill M.P.H., Ph.D. | Co-Founder, COO, Secretary & Director |
| Mr. Francisco D. Salva | President, CEO & Director |
| Mr. Norman Staskey | CFO & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | ARS | formars.pdf |
| 2026-04-27 | PRE 14A | formpre14a.htm |
| 2026-03-23 | 8-K | form8-k.htm |
| 2026-03-13 | 8-K | form8-k.htm |
| 2026-03-05 | DEFA14A | formdefa14a.htm |
| 2026-03-05 | 8-K | form8-k.htm |
| 2026-02-27 | 8-K | aztr-20260227.htm |
| 2026-02-27 | 10-K | aztr-20251231.htm |
| 2026-02-06 | DEFA14A | formdefa14a.htm |
| 2026-02-06 | 8-K | form8-k.htm |